Medicus Pharma reports positive phase 2 results for microneedle skin cancer treatment

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce the company has released topline results from its Phase 2 clinical study (SKNJCT-003) evaluating the safety and efficacy of its Doxorubicin Microneedle Array (D-MNA) for the non-invasive treatment of basal cell carcinoma of the skin. The company believes the topline data are not only positive but “decision-grade,” meaning they could support an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration in the first half of 2026 and help accelerate potential partnering discussions. Bokhari explained that the SKNJCT-003 clinical trial was designed as a randomized, double-blind, placebo-controlled, multi-center study involving 90 patients diagnosed with nodular basal cell carcinoma. The trial compared two dose levels of the D-MNA treatment with a placebo microneedle array control to assess both safety and therapeutic effectiveness. According to the results, clearance rates improved between Day 29 and Day 57, suggesting continued biological activity of the treatment over time. The higher-dose 200 microgram cohort demonstrated the strongest response by Day 57, achieving a 73% clinical clearance rate and a 40% histological clearance rate. The reported findings reflect analysis of the study’s primary and key secondary efficacy endpoints. Medicus Pharma noted that the final Clinical Study Report, which will include full safety analyses and additional procedural observations such as post-excisional biopsy site assessments, is still being compiled and is expected to be completed in the second quarter of 2026. While the final report remains in progress, the company said it does not anticipate any material changes to the efficacy findings reported in the topline results. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #RazaBokhari #Biotech #ClinicalTrials #Phase2Trial #BasalCellCarcinoma #SkinCancer #Doxorubicin #MicroneedleArray #DrugDelivery #FDA #BiotechInnovation #MedicalResearch #CancerTreatment #HealthcareInnovation #Biopharma